NCT02408861: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have HIV-1 infection
Exclusions: Known untreated brain or leptomeningeal metastases- see trial for details
https://ClinicalTrials.gov/show/NCT02408861

Comments are closed.

Up ↑